Table 1.
Derivation (MSKCC) (%) | Validation (European) (%) | p-value | |
---|---|---|---|
Total number of patients | 96 | 119 | |
Age (median, range) | 60 (29–88) | 62 (33–85) | NS |
Sex | |||
Male | 33 (34%) | 77 (65%) | < 0.0001 |
Female | 63 (66%) | 42 (35%) | |
Largest Tumor Size > 5cm | 22 (23%) | 38 (32%) | NS |
Primary Nodal Status | NS | ||
N+ | 56 (58%) | 59 (50%) | |
N− | 40 (42%) | 51 (43%) | |
Missing | 0 | 9 (8%) | |
> 1 tumor | 58 (60%) | 63 (53%) | NS |
DFI < 12 months | 51 (53%) | 72 (61%) | NS |
CEA > 200 | 8 (8.3%) | 13 (11%) | NS |
Neoadjuvant chemotherapy | 69 (72%) | 64 (54%) | < 0.01 |
Adjuvant chemotherapy | 79 (83%) | 68 (57%) | < 0.001 |
Adjuvant HAI chemotherapy | 34 (35%) | 0 (0%) | < 0.001 |
Type of resection | < 0.01 | ||
Minor (≤ 3 segments) | 44 (46%) | 76 (64%) | |
Major (> 3 segments) | 52 (54%) | 43 (36%) | |
Median follow up (months) | 89 | 25 | < 0.01 |